EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets

Jun Jiang iD, Donghui Han, Jiawei Wang iD, Weihong Wen, Rui Zhang, Weijun Qin iD

MedComm · 2024-10 · 5 (10)

DOI: 10.1002/mco2.761 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 04.10.2024. Verfasst von Jun Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Xijing Hospital Air Force Medical University Xi'an China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine transdifferentiation (NEtD), also commonly referred to as lineage plasticity, emerges as an acquired resistance mechanism to molecular targeted therapies in multiple cancer types, predominately occurs in metastatic epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors and metastatic castration‐resistant prostate cancer treated with androgen receptor targeting therapies. NEtD tumors are the lethal cancer histologic subtype with unfavorable prognosis and limited treatment. A comprehensive understanding of molecular mechanism underlying targeted‐induced plasticity could greatly facilitate the development of novel therapies. In the past few years, increasingly elegant studies indicated that NEtD tumors share key the convergent genomic and phenotypic characteristics irrespective of their site of origin, but also embrace distinct change and function of molecular mechanisms. In this review, we provide a comprehensive overview of the current understanding of molecular mechanism in regulating the NEtD, including genetic alterations, DNA methylation, histone modifications, dysregulated noncoding RNA, lineage‐specific transcription factors regulation, and other proteomic alterations. We also provide the current management of targeted therapies in clinical and preclinical practice.

Schlagwörter

Stichwörter der Autor:innen

acquired resistancelineage plasticityneuroendocrine prostate cancerneuroendocrine transdifferentiationsmall cell lung cancer

Autor:innen und Institutionen

  • Department of Urology Xijing Hospital Air Force Medical University Xi'an China.
  • Department of Health Service, Base of Health Service Air Force Medical University Xi'an China.
  • Department of Clinical Immunology, PLA Specialized Research Institute of Rheumatology & Immunology, Xijing Hospital, and National Translational Science Center for Molecular Medicine Air Force Medical University Xi'an Ch…
  • Xi'an Key Laboratory of Stem Cell and Regenerative Medicine, Institute of Medical Research Northwestern Polytechnical University Xi'an China.
  • State Key Laboratory of Cancer Biology Department of Immunology Air Force Medical University Xi'an China.

ORCID-Profile: Jun Jiang, Jiawei Wang, Weijun Qin

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Jiang, J., Han, D., Wang, J., Wen, W., Zhang, R., & Qin, W. (2024). Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets. MedComm, 5(10). https://doi.org/10.1002/mco2.761

Vancouver

Jiang J, Han D, Wang J, Wen W, Zhang R, Qin W. Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets. MedComm. 2024;5(10). doi:10.1002/mco2.761

BibTeX
@article{Jiang2024,
  author = {Jiang, Jun and Han, Donghui and Wang, Jiawei and Wen, Weihong and Zhang, Rui and Qin, Weijun},
  title = {Neuroendocrine transdifferentiation in human cancer: molecular mechanisms and therapeutic targets},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {10},
  doi = {10.1002/mco2.761}
}
Kostenlos starten →